nach oben

Cellular Oncology

Erschienen in:

01.06.2014 | Original Paper

Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status

verfasst von: Lene Rask, Eva Balslev, Rolf Søkilde, Estrid Høgdall, Henrik Flyger, Jens Eriksen, Thomas Litman

Erschienen in: Cellular Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Therapeutic decisions in breast cancer are increasingly guided by prognostic and predictive biomarkers. Non-protein-coding microRNAs (miRNAs) have recently been found to be deregulated in breast cancers and, in addition, to be correlated with several clinico-pathological features. One of the most consistently up-regulated miRNAs is miR-21. Here, we specifically searched for differentially expressed miRNAs in high-risk breast cancer patients as compared to low-risk breast cancer patients. In the same patients, we also compared miR-21 expression with the expression of its presumed target PTEN.

Methods

Both microarray and RT-qPCR techniques were used to assess miRNA expression levels in lymph node-positive and -negative human invasive ductal carcinoma tissues. Simultaneously, PTEN protein expression levels were assessed using immunohistochemistry.

Results

miR-486-5p and miR-139-5p were found to be down-regulated in patients with lymph node metastases, whereas miR-21 was found to be up-regulated in patients with a positive lymph node status. miR-21 expression levels were found to significantly correlate with tumour size (r = 0.403, p = 0.009; Spearman’s rank), whereas no relation was found between miR-21 and PTEN expression levels (Kruskal-Wallis test).

Conclusion

Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.

Nur mit Berechtigung zugänglich

R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2012. CA Cancer J Clin 62, 10–29 (2012)PubMedCrossRef

B. Weigelt, F.C. Geyer, J.S. Reis-Filho, Histological types of breast cancer: how special are they? Mol Oncol 4, 192–208 (2010)PubMedCrossRef

N.J. Bundred, Prognostic and predictive factors in breast cancer. Cancer Treatment Reviews 27, 137–142 (2001)PubMedCrossRef

G. Cheng, S. Kurita, D.A. Torigian, A. Alavi, Current status of sentinel lymph-node biopsy in patients with breast cancer. Eur J Nucl Med Mol Imaging 38, 562–575 (2011)PubMedCrossRef

A. Goldhirsch, J.N. Ingle, R.D. Gelber, A.S. Coates, B. Thurlimann, H.J. Senn, Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20, 1319–1329 (2009)PubMedCentralPubMedCrossRef

J. Krol, I. Loedige, W. Filipowicz, The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11, 597–610 (2010)PubMed

I.A. Asangani, S.A. Rasheed, D.A. Nikolova, J.H. Leupold, N.H. Colburn, S. Post, H. Allgayer, MicroRNA-21 (miR-21) post-transcriptionally downregulates tumour suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27, 2128–2136 (2008)PubMedCrossRef

H.K. Oh, A.L. Tan, K. Das, C.H. Ooi, N.T. Deng, I.B. Tan, E. Beillard, J. Lee, K. Ramnarayanan, S.Y. Rha, N. Palanisamy, P.M. Voorhoeve, P. Tan, Genomic loss of miR-486 regulates tumour progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res 17, 2657–2667 (2011)PubMedCrossRef

Z. Lu, M. Liu, V. Stribinskis, C.M. Klinge, K.S. Ramos, N.H. Colburn, Y. Li, MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27, 4373–4379 (2008)PubMedCrossRef

10.

R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell Oncol 36, 1–7 (2013)CrossRef

11.

M.V. Iorio, M. Ferracin, C.G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, M. Fabbri, M. Campiglio, S. Menard, J.P. Palazzo, A. Rosenberg, P. Musiani, S. Volinia, I. Nenci, G.A. Calin, P. Querzoli, M. Negrini, C.M. Croce, MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65, 7065–7070 (2005)PubMedCrossRef

12.

A. Aigner, MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl) 89, 445–457 (2011)CrossRef

13.

M.D. Mattie, C.C. Benz, J. Bowers, K. Sensinger, L. Wong, G.K. Scott, V. Fedele, D. Ginzinger, R. Getts, C. Haqq, Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5, 24 (2006)PubMedCentralPubMedCrossRef

14.

A.J. Lowery, N. Miller, A. Devaney, R.E. McNeill, P.A. Davoren, C. Lemetre, V. Benes, S. Schmidt, J. Blake, G. Ball, M.J. Kerin, MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 11, R27 (2009)PubMedCentralPubMedCrossRef

15.

G.L. Huang, X.H. Zhang, G.L. Guo, K.T. Huang, K.Y. Yang, X. Shen, J. You, X.Q. Hu, Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 21, 673–679 (2009)PubMed

16.

S. Zhu, H. Wu, F. Wu, D. Nie, S. Sheng, Y.Y. Mo, MicroRNA-21 targets tumour suppressor genes in invasion and metastasis. Cell Res 18, 350–359 (2008)PubMedCrossRef

17.

L.X. Yan, Q.N. Wu, Y. Zhang, Y.Y. Li, D.Z. Liao, J.H. Hou, J. Fu, M.S. Zeng, J.P. Yun, Q.L. Wu, Y.X. Zeng, J.Y. Shao, Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumour growth. Breast Cancer Res 13, R2 (2011)PubMedCentralPubMedCrossRef

18.

L.X. Yan, X.F. Huang, Q. Shao, M.Y. Huang, L. Deng, Q.L. Wu, Y.X. Zeng, J.Y. Shao, MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14, 2348–2360 (2008)PubMedCentralPubMedCrossRef

19.

B. Qian, D. Katsaros, L. Lu, M. Preti, A. Durando, R. Arisio, L. Mu, H. Yu, High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat 117, 131–140 (2009)PubMedCrossRef

20.

F. Meng, R. Henson, H. Wehbe-Janek, K. Ghoshal, S.T. Jacob, T. Patel, MicroRNA-21 regulates expression of the PTEN tumour suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647–658 (2007)PubMedCrossRef

21.

L. Salmena, A. Carracedo, P.P. Pandolfi, Tenets of PTEN tumour suppression. Cell 133, 403–414 (2008)PubMedCrossRef

22.

S. Zhu, M.L. Si, H. Wu, Y.Y. Mo, MicroRNA-21 targets the tumour suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282, 14328–14336 (2007)PubMedCrossRef

23.

L. Rask, M. Fregil, E. Hogdall, C. Mitchelmore, J. Eriksen, Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumour invasion. Gene 517, 72–81 (2013)PubMedCrossRef

24.

R. Sokilde, B. Kaczkowski, A. Podolska, S. Cirera, J. Gorodkin, S. Moller, T. Litman, Global microRNA analysis of the NCI-60 cancer cell panel. Mol Cancer Ther 10, 375–384 (2011)PubMedCrossRef

25.

S. Griffiths-Jones, H.K. Saini, D. S. van and A. J. Enright, miRBase: tools for microRNA genomics. Nucleic Acids Res 36, D154–D158 (2008)PubMedCentralPubMedCrossRef

26.

A.I. Saeed, N.K. Bhagabati, J.C. Braisted, W. Liang, V. Sharov, E.A. Howe, J. Li, M. Thiagarajan, J.A. White, J. Quackenbush, TM4 microarray software suite. Methods Enzymol 411, 134–193 (2006)PubMedCrossRef

27.

A. Perren, L.P. Weng, A.H. Boag, U. Ziebold, K. Thakore, P.L. Dahia, P. Komminoth, J.A. Lees, L.M. Mulligan, G.L. Mutter, C. Eng, Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155, 1253–1260 (1999)PubMedCentralPubMedCrossRef

28.

S.F. Tavazoie, C. Alarcon, T. Oskarsson, D. Padua, Q. Wang, P.D. Bos, W.L. Gerald, J. Massague, Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147–152 (2008)PubMedCentralPubMedCrossRef

29.

W. Li, B. Zhao, Y. Jin, K. Ruan, Development of a low-cost detection method for miRNA microarray. Acta Biochim Biophys Sin (Shanghai) 42, 296–301 (2010)CrossRef

30.

C. Chen, D.A. Ridzon, A.J. Broomer, Z. Zhou, D.H. Lee, J.T. Nguyen, M. Barbisin, N.L. Xu, V.R. Mahuvakar, M.R. Andersen, K.Q. Lao, K.J. Livak, K.J. Guegler, Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33, e179 (2005)PubMedCentralPubMedCrossRef

31.

P.N. D’Andrade, S. Fulmer-Smentek, Agilent MicroRNA Microarray Profiling System. Methods Mol Biol 822, 85–102 (2012)PubMedCrossRef

32.

J.M. Lee, Y. Jung, Two-Temperature Hybridization for Microarray Detection of Label-Free MicroRNAs with Attomole Detection and Superior Specificity. Angew Chem Int Ed Engl 50, 12487–12490 (2011)PubMedCrossRef

33.

S. Tam, B. R. de, M. S. Tsao and J. D. McPherson, Robust global microRNA expression profiling using next-generation sequencing technologies. Lab Invest 94, 350–358 (2014)PubMedCrossRef

34.

Y. Nakamura, H. Yasuoka, M. Tsujimoto, S. Imabun, M. Nakahara, K. Nakao, M. Nakamura, I. Mori, K. Kakudo, Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 91, 125–132 (2005)PubMedCrossRef

35.

R. Heimann, D. Ferguson, S. Gray, S. Hellman, Assessment of intratumoural vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Res Treat 52, 147–158 (1998)PubMedCrossRef

36.

G.P. Gupta, J. Massague, Cancer metastasis: building a framework. Cell 127, 679–695 (2006)PubMedCrossRef

37.

S. Eccles, L. Paon, J. Sleeman, Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis 24, 619–636 (2007)PubMedCrossRef

38.

A. Smeets, A. Daemen, B. Vanden, I, O. Gevaert, B. Claes, H. Wildiers, R. Drijkoningen, H. P. Van, D. Lambrechts, M. B. De, P. Neven, C. Sotiriou, T. Vandorpe, R. Paridaens and M. R. Christiaens, Prediction of lymph node involvement in breast cancer from primary tumour tissue using gene expression profiling and miRNAs. Breast Cancer Res Treat 129, 767–776 (2011)PubMedCrossRef

39.

R. Baffa, M. Fassan, S. Volinia, B. O’Hara, C.G. Liu, J.P. Palazzo, M. Gardiman, M. Rugge, L.G. Gomella, C.M. Croce, A. Rosenberg, MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219, 214–221 (2009)PubMedCrossRef

40.

R. Navon, H. Wang, I. Steinfeld, A. Tsalenko, A. Ben-Dor, Z. Yakhini, Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS ONE 4, e8003 (2009)PubMedCentralPubMedCrossRef

41.

L. Yu, N.W. Todd, L. Xing, Y. Xie, H. Zhang, Z. Liu, H. Fang, J. Zhang, R.L. Katz, F. Jiang, Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 127, 2870–2878 (2010)PubMedCentralPubMedCrossRef

42.

S. Koshida, D. Kobayashi, R. Moriai, N. Tsuji, N. Watanabe, Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci 98, 315–320 (2007)PubMedCrossRef

43.

S.T. Mees, W.A. Mardin, S. Sielker, E. Willscher, N. Senninger, C. Schleicher, M. Colombo-Benkmann, J. Haier, Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 16, 2339–2350 (2009)PubMedCrossRef

44.

C.H. Stuelten, D.S. Salomon, miR-31 in cancer: location matters. Cell Cycle 9, 4608–4609 (2010)PubMedCrossRef

45.

S. Corbetta, V. Vaira, V. Guarnieri, A. Scillitani, C. Eller-Vainicher, S. Ferrero, L. Vicentini, I. Chiodini, M. Bisceglia, P. Beck-Peccoz, S. Bosari, A. Spada, Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer 17, 135–146 (2010)PubMedCrossRef

46.

Y. Ma, P. Zhang, J. Yang, Z. Liu, Z. Yang, H. Qin, Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer 130, 2077–2087 (2012)PubMedCrossRef

47.

T.S. Wong, X.B. Liu, B.Y. Wong, R.W. Ng, A.P. Yuen, W.I. Wei, Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 14, 2588–2592 (2008)PubMedCrossRef

48.

C.C. Wong, C.M. Wong, E.K. Tung, S.L. Au, J.M. Lee, R.T. Poon, K. Man, I.O. Ng, The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 140, 322–331 (2011)PubMedCrossRef

49.

R.L. Skalsky, B.R. Cullen, Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS ONE 6, e24248 (2011)PubMedCentralPubMedCrossRef

50.

C. Mascaux, J.F. Laes, G. Anthoine, A. Haller, V. Ninane, A. Burny, J.P. Sculier, Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J 33, 352–359 (2009)PubMedCrossRef

51.

W. Bao, H.J. Fu, Q.S. Xie, L. Wang, R. Zhang, Z.Y. Guo, J. Zhao, Y.L. Meng, X.L. Ren, T. Wang, Q. Li, B.Q. Jin, L.B. Yao, R.A. Wang, D.M. Fan, S.Y. Chen, L.T. Jia, A.G. Yang, HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 141, 2076–2087 (2011)PubMedCrossRef

52.

H. Yamashita, M. Nishio, T. Toyama, H. Sugiura, Z. Zhang, S. Kobayashi, H. Iwase, Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6, R24–R30 (2004)PubMedCentralPubMedCrossRef

53.

S.U. Woo, J.W. Bae, C.H. Kim, J.B. Lee, B.W. Koo, A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol 15, 281–285 (2008)PubMedCrossRef

54.

L. Rask, E. Balslev, S. Jorgensen, J. Eriksen, H. Flyger, S. Moller, E. Hogdall, T. Litman, B.S. Nielsen, High expression of miR-21 in tumour stroma correlates with increased cancer cell proliferation in human breast cancer. APMIS 119, 663–673 (2011)PubMedCrossRef

55.

L.F. Sempere, M. Preis, T. Yezefski, H. Ouyang, A.A. Suriawinata, A. Silahtaroglu, J.R. Conejo-Garcia, S. Kauppinen, W. Wells, M. Korc, Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumours. Clin Cancer Res 16, 4246–4255 (2010)PubMedCentralPubMedCrossRef

56.

R. Kalluri, M. Zeisberg, Fibroblasts in cancer. Nat Rev Cancer 6, 392–401 (2006)CrossRef

57.

Q. Yao, S. Cao, C. Li, A. Mengesha, B. Kong, M. Wei, Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumour-stroma interaction. Int J Cancer 128, 1783–1792 (2011)PubMedCrossRef

58.

R. Madhyastha, H. Madhyastha, Y. Nakajima, S. Omura, M. Maruyama, MicroRNA signature in diabetic wound healing: promotive role of miR-21 in fibroblast migration. Int Wound J 9, 355–361 (2012)PubMedCrossRef

59.

L. Qi, J. Bart, L.P. Tan, I. Platteel, T. Sluis, S. Huitema, G. Harms, L. Fu, H. Hollema, A. Berg, Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9, 163 (2009)PubMedCentralPubMedCrossRef

60.

M.S. Alexander, J.C. Casar, N. Motohashi, J.A. Myers, I. Eisenberg, R.T. Gonzalez, E.A. Estrella, P.B. Kang, G. Kawahara, L.M. Kunkel, Regulation of DMD pathology by an ankyrin-encoded miRNA. Skelet Muscle 1, 27 (2011)PubMedCentralPubMedCrossRef

Titel: Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status
verfasst von: Lene Rask
Eva Balslev
Rolf Søkilde
Estrid Høgdall
Henrik Flyger
Jens Eriksen
Thomas Litman
Publikationsdatum: 01.06.2014
Verlag: Springer Netherlands
Erschienen in: Cellular Oncology / Ausgabe 3/2014
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-014-0176-6

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Automated classification of oral premalignant lesions using image cytometry and Random Forests-based algorithms

Identification of GPM6A and GPM6B as potential new human lymphoid leukemia-associated oncogenes

The cancer genome: from structure to function

Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents - implications for cancer treatment and chemoprevention

Expression of H1.5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report

Retinoblastoma (RB1) pocket domain mutations and promoter hyper-methylation in head and neck cancer

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien